化工进展2016，Vol.35Issue(12)：3985-3990,6.DOI:10.16085/j.issn.1000-6613.2016.12.035
间变性淋巴瘤激酶抑制剂的研究进展
Advances in research on anaplastic lympgoma kinase inhibitors
摘要
Abstract
Researchers have found that multiple oncogenic driver multations are closely related with the progression and prognosis of NSCLC.In the era of molecular targeted treatment,rearrangements in anaplastic lymphoma kinase(ALK)gene and echinoderm microtubule-associated protein-like 4 (EML4)gene were applied in patients with non-small cell lung cancer(NSCLC). Crizotinib,an ALK inhibitor,is effective in treating advanced ALK-positive NSCLC,and the US Food and Drug Administration(FDA)approved it for treating ALK-positive NSCLC. Several mechanisms of acquired resistance to crizotinib have recently been reported. Second-generation ALK inhibitors were developed to overcome these resistance mechanisms and showed activity againstALKpositive NSCLC. The latest development of crizotinib,ceritinib,alectinibetc. were reviewed.关键词
非小细胞肺癌/EML4-ALK基因重排/克唑替尼Key words
non small cell lung cancer/echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement/crizotinib分类
信息技术与安全科学引用本文复制引用
陈雅琳,李巍,汪天洋,周雪琴,刘东志..间变性淋巴瘤激酶抑制剂的研究进展[J].化工进展,2016,35(12):3985-3990,6.基金项目
天津市科技创新平台计划（14TXGCCX00017）项目。 （）
